Update on the mechanism of action of bimatoprost: a review and discussion of new evidence.
Krauss Achim H-P, Woodward David F
AI Summary
Bimatoprost's glaucoma mechanism involves mimicking prostamides via anandamide/COX-2, acting as a prodrug, or direct FP receptor stimulation, with ongoing research clarifying these hypotheses.
Abstract
Bimatoprost is a pharmacologically unique and highly efficacious anti-glaucoma agent. It appears to mimic the activity of the prostamides, which are biosynthesized from the natural endocannabinoid anandamide by the enzyme cyclo-oxygenase 2 (COX-2). Bimatoprost has also been suggested to lower intraocular pressure by behaving as a prodrug or, alternatively, by stimulating FP receptors directly. These three distinctly different hypotheses for the mechanism of bimatoprost activity are discussed in the light of current evidence.
MeSH Terms
Shields Classification
Related Articles5
Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
Randomized Controlled TrialEfficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment.
Randomized Controlled TrialEffects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability.
Clinical TrialLatanoprost as a new horizon in the medical management of glaucoma.
ReviewMultiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics.
Basic ScienceIs this article assigned to the wrong chapter(s)? Let us know.